Secure Drug & Device Compatibility & Commercial Viability to Advance Best in Class Intranasal Treatment for CNS, Emergency-Use, Neurological & Infectious Diseases for Unparalleled Patient Efficacy
The 4th Nasal Formulation & Delivery Summit united formulation, delivery, and product development leaders from across pharma and biotech to advance the development of safe, effective, and commercially viable intranasal therapies. As intranasal delivery gained validation across systemic, CNS, and emergency-use indications, the pressure to optimize formulations, align drug–device strategies, and generate predictive preclinical and clinical data had never been greater.
In an era of accelerating approvals, expanding modalities, and heightened regulatory scrutiny, teams had to move beyond proof-of-concept to ensure intranasal programs are scalable, translatable, and fit for commercialization. Success depended on solving formulation and delivery challenges early, while designing development strategies that withstand clinical, regulatory, and manufacturing demands.
We united 60+ experts from Eli Lilly, Bayer, Neurelis, Virpax Pharmaceuticals, Belhaven Biopharma, and more to explore real-world preclinical and clinical data, compare liquid and powder nasal approaches, and align on best practices for systemic and nose-to-brain delivery. This was the only industry-led meeting dedicated exclusively to end-to-end intranasal formulation, delivery, and commercialization.
World-Class 2026 Speaker Faculty
Attending Companies Included